After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...